Latest News and Press Releases
Want to stay updated on the latest news?
-
SAN FRANCISCO and SHANGHAI, June 01, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
-
SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
-
12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and...
-
硕迪生物 2023 年第一季度财务报告及近期亮点 Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity用于治疗 2 型糖尿病和肥胖症的口服 GLP-1 激动剂 GSBR-1290 项目已推进到临床2a期。 Topline data from Phase...
-
SAN FRANCISCO and SHANGHAI, China, May 18, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
-
Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half...
-
口服GLP-1激动剂GSBR-1290 Phase 1b研究已完成给药预计2023年下半年将获得GSBR-1290 Phase 1b和Phase 2a研究的数据已完成总额为1.853亿美元的扩大规模首次公开募股 旧金山和上海, April 05, 2023 (GLOBE NEWSWIRE) --...
-
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023Completed $185.3 million upsized initial public...
-
旧金山和上海, Feb. 08, 2023 (GLOBE NEWSWIRE) --...
-
SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...